Reply to Rumrich and colleagues (What does “Parkinson’s disease mortality” mean?)

Related Articles:

• Reply to Rumrich and colleagues (What does "Parkinson's disease mortality" mean?) March 17, 2023 Environ Int. 2023 Mar;173:107853. doi: 10.1016/j.envint.2023.107853. Epub 2023 Mar 15.NO ABSTRACTPMID:36931779 | DOI:10.1016/j.envint.2023.107853
• Reply to Rumrich and colleagues (What does "Parkinson's disease mortality" mean?) March 17, 2023 Environ Int. 2023 Mar;173:107853. doi: 10.1016/j.envint.2023.107853. Epub 2023 Mar 15.NO ABSTRACTPMID:36931779 | DOI:10.1016/j.envint.2023.107853
• Reply to Rumrich and colleagues (What does "Parkinson's disease mortality" mean?) March 17, 2023 Environ Int. 2023 Mar;173:107853. doi: 10.1016/j.envint.2023.107853. Epub 2023 Mar 15.NO ABSTRACTPMID:36931779 | DOI:10.1016/j.envint.2023.107853
• Reply to Rumrich and colleagues (What does "Parkinson's disease mortality" mean?) March 17, 2023 Environ Int. 2023 Mar;173:107853. doi: 10.1016/j.envint.2023.107853. Epub 2023 Mar 15.NO ABSTRACTPMID:36931779 | DOI:10.1016/j.envint.2023.107853
• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• Be one with Vitamin B1 April 13, 2022     # # # # BEFORE WE START: There are some topics that I am reluctant to address on this website, because there are folks within the community who have extremely vested interests in them. Thiamine (or Vitamin B1) is one of those topics. Some members of the Parkinson’s community have indicated to me that high doses of this…
• Mind blowing modulation of mind October 12, 2021 # # # # Neuromodulation of specific circuits in the brain represents a means of adjusting deficits in neural performance and significantly improving quality of life. Deep brain stimulation has been widely applied to the treatment of Parkinson’s since Alim Benabid first discovered that electrical stimulation of the basal ganglia improves the symptoms of the condition in the late 1980s.…
• Letter in response to Cole-Hunter et al., 2023: What does "Parkinson's disease mortality" mean? March 17, 2023 Environ Int. 2023 Mar;173:107852. doi: 10.1016/j.envint.2023.107852. Epub 2023 Mar 15.NO ABSTRACTPMID:36931780 | DOI:10.1016/j.envint.2023.107852
• Letter in response to Cole-Hunter et al., 2023: What does "Parkinson's disease mortality" mean? March 17, 2023 Environ Int. 2023 Mar;173:107852. doi: 10.1016/j.envint.2023.107852. Epub 2023 Mar 15.NO ABSTRACTPMID:36931780 | DOI:10.1016/j.envint.2023.107852
• Letter in response to Cole-Hunter et al., 2023: What does "Parkinson's disease mortality" mean? March 17, 2023 Environ Int. 2023 Mar;173:107852. doi: 10.1016/j.envint.2023.107852. Epub 2023 Mar 15.NO ABSTRACTPMID:36931780 | DOI:10.1016/j.envint.2023.107852
• Letter in response to Cole-Hunter et al., 2023: What does "Parkinson's disease mortality" mean? March 17, 2023 Environ Int. 2023 Mar;173:107852. doi: 10.1016/j.envint.2023.107852. Epub 2023 Mar 15.NO ABSTRACTPMID:36931780 | DOI:10.1016/j.envint.2023.107852
• Letter in response to Cole-Hunter et al., 2023: What does "Parkinson's disease mortality" mean? March 17, 2023 Environ Int. 2023 Mar;173:107852. doi: 10.1016/j.envint.2023.107852. Epub 2023 Mar 15.NO ABSTRACTPMID:36931780 | DOI:10.1016/j.envint.2023.107852
• The terazosin pilot study results December 16, 2021 # # # # Drug repurposing represents a means of rapidly testing and bring novel therapies to the patient. By testing clinically available drugs – that have well characterised safety records in a particular medical condition – one can determine if a certain biological pathway is playing an influential role in another disease. A good example of this is work…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• Can shaking hands fix shaking hands? December 5, 2022 # # # # Novel treatments for Parkinson’s are being proposed on a regular basis, and I really like the way many are based on some pretty left field ideas (light buckets, I’m thinking of you here). Thinking outside the box is important to innovation and progress. And some of those unconventional approaches are backed not only by historical precedent,…
• ADepTing to the UCB-Novartis deal December 6, 2021 # # # # Alpha synuclein has long been viewed at “Public enemy #1” by the Parkinson’s research community. This sticky, abundant protein starts to cluster (or aggregate) in Parkinson’s. There have been several attempts to reduce levels of the protein floating around outside of cells (using “immunotherapy” approaches) But now clinical research is ramping up to determine if reducing…
• Parkinson’s research in Nigeria March 20, 2022 # # # # In an effort to highlight under-represented populations within the Parkinson’s community world-wide, today we will look at some recent research that has been conducted in the central African republic of Nigeria. Nigeria is a nation of more than 200 million people. Despite a lower general life expectancy rate, the country does have a large Parkinson’s community.…
• Long-term exposure to residential greenness and neurodegenerative disease mortality among older adults: a 13-year follow-up cohort study May 7, 2022 Environ Health. 2022 May 7;21(1):49. doi: 10.1186/s12940-022-00863-x.ABSTRACTBACKGROUND: Living in greener areas is associated with slower cognitive decline and reduced dementia risk among older adults, but the evidence with neurodegenerative disease mortality is scarce. We studied the association between residential surrounding greenness and neurodegenerative disease mortality in older adults.METHODS: We used data from the 2001 Belgian census linked to mortality register…
• Long-term exposure to residential greenness and neurodegenerative disease mortality among older adults: a 13-year follow-up cohort study May 7, 2022 Environ Health. 2022 May 7;21(1):49. doi: 10.1186/s12940-022-00863-x.ABSTRACTBACKGROUND: Living in greener areas is associated with slower cognitive decline and reduced dementia risk among older adults, but the evidence with neurodegenerative disease mortality is scarce. We studied the association between residential surrounding greenness and neurodegenerative disease mortality in older adults.METHODS: We used data from the 2001 Belgian census linked to mortality register…
• Long-term exposure to residential greenness and neurodegenerative disease mortality among older adults: a 13-year follow-up cohort study May 7, 2022 Environ Health. 2022 May 7;21(1):49. doi: 10.1186/s12940-022-00863-x.ABSTRACTBACKGROUND: Living in greener areas is associated with slower cognitive decline and reduced dementia risk among older adults, but the evidence with neurodegenerative disease mortality is scarce. We studied the association between residential surrounding greenness and neurodegenerative disease mortality in older adults.METHODS: We used data from the 2001 Belgian census linked to mortality register…
• Long-term exposure to residential greenness and neurodegenerative disease mortality among older adults: a 13-year follow-up cohort study May 7, 2022 Environ Health. 2022 May 7;21(1):49. doi: 10.1186/s12940-022-00863-x.ABSTRACTBACKGROUND: Living in greener areas is associated with slower cognitive decline and reduced dementia risk among older adults, but the evidence with neurodegenerative disease mortality is scarce. We studied the association between residential surrounding greenness and neurodegenerative disease mortality in older adults.METHODS: We used data from the 2001 Belgian census linked to mortality register…